Cell No. : Cell Name
RCB0819 : HMMME
update : 2024/08/14
|
| Comment | Human cell line derived from malignant mesothelioma. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Ishiwata, Isamu
|
| Originator |
Ishiwata, I. & Ishikawa, H. & Ishioka, K.
|
| Year of deposit |
1992
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
72 years
|
| Tissue |
pleural effusion
|
| Disease name |
mesothelioma
|
| Classification |
cancer
|
| Year of origin |
1991
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_8163
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
HamF12 + 15% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : once/2 weeks, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
42-84(50) : /79(7),80(1),81(3),82(1),83(3),84(23)
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
0
|
| User's Publication |
5
|
| User's Publication |
|
19954
Okamura K, Inoue H, Tanaka K, Ikematsu Y, Furukawa R, Ota K, Yoneshima Y, Iwama E, Okamoto I.
Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma
Cancer Sci
2023
114(3):1095-1107
PubMed ID: 36369966
DOI: 10.1111/cas.15645
|
|
13582
Kaneda A, Seike T, Danjo T, Nakajima T, Otsubo N, Yamaguchi D, Tsuji Y, Hamaguchi K, Yasunaga M, Nishiya Y, Suzuki M, Saito JI, Yatsunami R, Nakamura S, Sekido Y, Mori K.
The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma
Am J Cancer Res
2020
10(12):4399-4415
PubMed ID: 33415007
|
|
14252
Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.
Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification
Int J Oncol
2017
50(1):129-140.
PubMed ID: 27922671
DOI: 10.3892/ijo.2016.3786
|
|
8199
Hasegawa S, Koshikawa-Yano M, Saito S, Morokoshi Y, Furukawa T, Aoki I, Saga T.
Molecular imaging of mesothelioma by detection of manganese-superoxide dismutase activity using manganese-enhanced magnetic resonance imaging.
Int. J. Cancer
2011
128:2138-46
PubMed ID: 20617513
DOI: 10.1002/ijc.25547
|
|
5877
Yamamoto H, Okumura K, Toshima S, Mukaisho K, Sugihara H, Hattori T, Kato M, Asano S.
FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues.
Biol Pharm Bull
2009
32(7):1148-54
PubMed ID: 19571376
DOI: 10.1248/bpb.32.1148
|
Back
Top
CELL BANK Website